pharma operations – Page 51

Method development instability during transfer to manufacturing – data package improvements for filing

Addressing Method Development Instability When Transitioning to Manufacturing In the competitive landscape of pharmaceutical development, the stability of analytical methods during the transfer to manufacturing can pose significant challenges. Inconsistent…

Tech transfer readiness gaps during early development – downstream GMP risk and prevention

Addressing Readiness Gaps in Tech Transfer to Mitigate GMP Risks In the realm of pharmaceutical manufacturing, tech transfer during early development phases can present significant challenges. Often overlooked, these readiness…

Scale-up risk not identified during pilot scale – how to ensure smooth tech transfer

Addressing Unidentified Scale-Up Risks During Pilot Scale in Pharmaceutical Development In the pharmaceutical industry, the transition from pilot scale to full production can be fraught with risks that may not…

Method transfer mismatch in stability testing – how to distinguish lab error vs true failure

Identifying and Addressing Method Transfer Mismatch in Stability Testing In a pharmaceutical manufacturing environment, detecting a method transfer mismatch in stability testing can be a significant concern. Such discrepancies not…

Tech transfer readiness gaps during transfer to manufacturing – regulatory scrutiny implications

Understanding Tech Transfer Readiness Gaps and Their Regulatory Implications in Manufacturing In the life sciences sector, successful tech transfer to manufacturing is critical for maintaining compliance with Good Manufacturing Practices…

OOS investigation lacks root cause during data review and approval – CAPA package with objective evidence

OOS Investigations: Navigating Root Cause Challenges in Data Review and Approval In the pharmaceutical manufacturing environment, Out-of-Specification (OOS) results pose significant compliance challenges. A scenario often encountered is the lack…

Excipient variability impact during comparability assessment – regulatory scrutiny implications

Understanding the Impact of Excipient Variability in Comparability Assessments and Its Regulatory Implications The pharmaceutical industry faces a myriad of challenges when it comes to maintaining compliance and ensuring product…

Unplanned process deviation during night shift operations – batch disposition decision tree for QA alignment

Addressing Unplanned Process Deviations During Night Shift Operations in Pharma Manufacturing In the highly regulated field of pharmaceutical manufacturing, unplanned process deviations can occur unexpectedly, particularly during night shift operations…

Excipient variability impact during pilot scale – downstream GMP risk and prevention

Understanding the Impact of Excipient Variability During Pilot Scale on Downstream GMP Risks and Preventive Strategies The pharmaceutical industry faces numerous challenges during the production process, particularly when transitioning from…

Breakdown repair undocumented during seasonal HVAC load changes – calibration/PM evidence pack checklist

Uncovering Causes of Undocumented Breakdown Repairs in Seasonal HVAC Adjustments Seasonal load changes in HVAC systems pose significant challenges for pharmaceutical manufacturing facilities, which rely heavily on consistent temperature and…

Method development instability during pilot scale – how to ensure smooth tech transfer

Ensuring Effective Tech Transfer: Addressing Method Development Instability During Pilot Scale Method development instability during pilot scale can be a critical issue, leading to inconsistent results and potential regulatory hurdles.…

Breakdown repair undocumented after equipment breakdown – calibration/PM evidence pack checklist

Undocumented Equipment Breakdown Repairs: A Comprehensive Investigation Approach Breakdowns of manufacturing equipment can lead to significant disruptions, especially when repairs are undocumented. Such situations may raise substantial concerns during audits…